The HHS is committed to finishing its $400 million deal with Emergent BioSolutions for supplies of the anthrax vaccine BioThrax, the company announced. Emergent already released $42 million worth of BioThrax doses for pre-exposure vaccination. Approval of the drug as a post-exposure vaccine would entitle the company to another $11.5 million from the HHS.

Related Summaries